The precursor of Alzheimer's disease amyloid A4 protein resembles a cell-surface receptor
The DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.
Abstract
Alzheimer's disease is characterized by a widespread functional disturbance of the human brain. Fibrillar amyloid proteins are deposited inside neurons as neurofibrillary tangles and extracellularly as amyloid plaque cores and in blood vessels. The major protein subunit (A4) of the amyloid fibril of tangles, plaques and blood vessel deposits is an insoluble, highly aggregating small polypeptide of relative molecular mass 4,500. The same polypeptide is also deposited in the brains of aged individuals with trisomy 21 (Down's syndrome). We have argued previously that the A4 protein is of neuronal origin and is the cleavage product of a larger precursor protein. To identify this precursor, we have now isolated and sequenced an apparently full-length complementary DNA clone coding for the A4 polypeptide. The predicted precursor consists of 695 residues and contains features characteristic of glycosylated cell-surface receptors. This sequence, together with the localization of its gene on chromosome 21, suggests that the cerebral amyloid deposited in Alzheimer's disease and aged Down's syndrome is caused by aberrant catabolism of a cell-surface receptor.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Molecular imaging studies such as those using amyloid positron emission tomography (PET) have shown that Aβ deposition reaches a plateau before brain atrophy can be identified from structural magnetic resonance imaging (MRI) and cognitive symptoms [15, 19].”
From Clinical trials of new drugs for Alzheimer disease (2020) · cites this paper as [15]
In the citing paper
“All the mutant genes of hereditary, autosomal, and dominant familial AD, including amyloid precursor protein (APP), presenilin 1, and presenilin 2, encode the major proteins involved in amyloid metabolism [14–16].”
From Clinical trials of new drugs for Alzheimer disease (2020) · cites this paper as [15]
In the citing paper
“Amyloid  protein (A), the principal protein in the senile plaques of Alzheimer's disease (AD), is an ϳ4 kDa secreted polypeptide”
From Age-Dependent Changes in Brain, CSF, and Plasma Amyloid β Protein in the Tg2576 Transgenic Mouse Model of Alzheimer's Disease (2001) · cites this paper as Kang et al., 1987
In the citing paper
“APP isoforms are encoded by several alternatively spliced transcripts (Kang et al., 1987;K itaguchi et al., 1988;Ponte et al., 1988;Tanzi et al., 1988;Golde et al., 1990;Ko ¨nig et al., 1992).”
From Alzheimer Amyloid Protein Precursor in the Rat Hippocampus: Transport and Processing through the Perforant Path (1998) · cites this paper as Kang et al., 1987
In the citing paper
“APP, first identified by Kang et al. [18], is a type I transmembrane protein with a long luminal N-terminal domain and a small cytoplasmic C-terminal tail [18,19].”
From Advances in the cell biology of the trafficking and processing of amyloid precursor protein: impact of familial Alzheimer's disease mutations (2024) · cites this paper as [18]
Citations
Cites
DNA sequencing with chain-terminating inhibitors
Sanger, F., Nicklen, S., & Coulson, A. R. (1977) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.74.12.5463 · Cited by 68,572
Detection of specific sequences among DNA fragments separated by gel electrophoresis
Southern, E. M. (1975) · Journal of Molecular Biology · doi:10.1016/s0022-2836(75)80083-0 · Cited by 32,249
Rigby, P. W. J., Dieckmann, M., Rhodes, C., & Berg, P. (1977) · Journal of Molecular Biology · doi:10.1016/0022-2836(77)90052-3 · Cited by 11,401
Hybridization of denatured RNA and small DNA fragments transferred to nitrocellulose.
Thomas, P. S. (1980) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.77.9.5201 · Cited by 8,156
Aviv, H., & Leder, P. (1972) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.69.6.1408 · Cited by 6,751
Amyloid plaque core protein in Alzheimer disease and Down syndrome.
Masters, C. L., Simms, G., Weinman, N. A., Multhaup, G., McDonald, B. L., & Beyreuther, K. (1985) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.82.12.4245 · Cited by 4,431
Self-citationLehrach, H., Diamond, D., Wozney, J. M., & Boedtker, H. (1977) · Biochemistry · doi:10.1021/bi00640a033 · Cited by 3,415
A gas-liquid solid phase peptide and protein sequenator.
Hewick, R. M., Hunkapiller, M. W., Hood, L. E., & Dreyer, W. J. (1981) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)43377-7 · Cited by 2,218
Alzheimer's disease and Down's syndrome: Sharing of a unique cerebrovascular amyloid fibril protein
Glenner, G. G., & Wong, C. W. (1984) · Biochemical and Biophysical Research Communications · doi:10.1016/0006-291x(84)91209-9 · Cited by 1,693
A cellular gene encodes scrapie PrP 27-30 protein
Oesch, B., Westaway, D., Wälchli, M., McKinley, M. P., Kent, S. B. H., Aebersold, R., Barry, R. A., Tempst, P., Teplow, D. B., Hood, L. E., et al. (1985) · Cell · doi:10.1016/0092-8674(85)90333-2 · Cited by 1,513
Research works printed but not linked: 4
- Alzheimer, A. Allg. Z. Psychiat. 64, 146–148 (1907).
- Katzman, R. (ed.) Biological Aspects of Alzheimer's Disease (Banbury Report 15) (Cold Spring Harbor Laboratory, New York, 1983).
- Beyreuther, K. et al. in Discussions in Neuroscience Vol. 3 (eds Bignami, A., Bolis, L. & Gajdusek, D. C. 68–79 Fondation pour I'Étude du Système Nerveux, Geneva (1986).
- Goldgaber, D., Lerman, M. I., McBride, W. O., Sallow, V. & Gajdusek, D. C. Science (in the press).
Cited by
Items 701–800 of 1,071
Pereira, C., Santos, M. S., & Oliveira, C. (1999) · Neurobiology of Disease · doi:10.1006/nbdi.1999.0241 · Cited by 156
“The amyloid b-peptide, the major component of neuritic plaques, is a 40- to 42-amino-acid proteolytic fragment of the amyloid precursor protein (Kang et al., 1987).”
BackgroundDurk, M. R., Han, K., Chow, E. C. Y., Ahrens, R., Henderson, J. T., Fraser, P. E., & Pang, K. S. (2014) · The Journal of Neuroscience · doi:10.1523/jneurosci.2711-13.2014 · Cited by 156
“A peptides are formed by cleavage of the amyloid precursor protein (APP) via - and -secretases (Kang et al., 1987; Haass et al., 1992; Hartmann et al., 1997; Weidemann et al., 1999).”
BackgroundNanomaterials for Drug Delivery to the Central Nervous System
Teleanu, D. M., Negut, I., Grumezescu, V., Grumezescu, A. M., & Teleanu, R. I. (2019) · Nanomaterials · doi:10.3390/nano9030371 · Cited by 156
“The neuropathology of AD is commonly linked to the subsequent cloning of the gene responsible for encoding the β-amyloid precursor protein (APP) and its localization to chromosome 21 [91,92], together with the earlier recognition of trisomy 21 (Downs syndrome) [93].”
BackgroundTacnet-Delorme, P., Chevallier, S., & Arlaud, G. J. (2001) · The Journal of Immunology · doi:10.4049/jimmunol.167.11.6374 · Cited by 156
“It is characterized by excessive deposition in the CNS of the -amyloid peptide, a 40- to 42-residue peptide derived from a larger precursor protein (1, 2).”
BackgroundFossgreen, A., Brückner, B., Czech, C., Masters, C. L., Beyreuther, K., & Paro, R. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.23.13703 · Cited by 156
Self-citationTanaka, S., Nakamura, S., Ueda, K., Kameyama, M., Shiojiri, S., Takahashi, Y., Kitaguchi, N., & Ito, H. (1988) · Biochemical and Biophysical Research Communications · doi:10.1016/s0006-291x(88)80273-0 · Cited by 156
Otsuka, N., Tomonaga, M., & Ikeda, K. (1991) · Brain Research · doi:10.1016/0006-8993(91)91422-w · Cited by 162
Card, J. P., Meade, R. P., & Davis, L. G. (1988) · Neuron · doi:10.1016/0896-6273(88)90131-6 · Cited by 160
Arai, H., Lee, V. M., Otvos, L., Greenberg, B. D., Lowery, D. E., Sharma, S. K., Schmidt, M. L., & Trojanowski, J. Q. (1990) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.87.6.2249 · Cited by 155
Mattson, M. P. (1994) · PubMed · Cited by 154
Tomiyama, T., Asano, S., Furiya, Y., Shirasawa, T., Endo, N., & Mori, H. (1994) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(17)34045-0 · Cited by 154
β‐Amyloid precursor protein is modified with O‐linked N‐acetylglucosamine
Griffith, L. S., Mathes, M., & Schmitz, B. (1995) · Journal of Neuroscience Research · doi:10.1002/jnr.490410214 · Cited by 154
“The importance of proteolytic cleavage (Kang et al., 1987; Selkoe, 1990, 1994), and the possible involvement of phosphorylation (Gandy et al.”
BackgroundAmyloid β protein in plasma from patients with sporadic Alzheimer's disease
Tamaoka, A., Fukushima, T., Sawamura, N., Ishikawa, K., Oguni, E., Komatsuzaki, Y., & Shoji, S. (1996) · Journal of the Neurological Sciences · doi:10.1016/0022-510x(96)00143-8 · Cited by 156
Amyloid β protein precursor and the pathogenesis of Alzheimer's disease
Selkoe, D. J. (1989) · Cell · doi:10.1016/0092-8674(89)90093-7 · Cited by 154
The Genetics of the Amyloidoses
Buxbaum, J. N., & Tagoe, C. E. (2000) · Annual Review of Medicine · doi:10.1146/annurev.med.51.1.543 · Cited by 171
RACCHI, M., BAETTA, R., SALVIETTI, N., IANNA, P., FRANCESCHINI, G., PAOLETTI, R., FUMAGALLI, R., GOVONI, S., TRABUCCHI, M., & SOMA, M. (1997) · Biochemical Journal · doi:10.1042/bj3220893 · Cited by 154
Hardy, J. (2017) · The FEBS Journal · doi:10.1111/febs.14004 · Cited by 153
Alifragis, P., & Marsh, J. (2018) · Neural Regeneration Research · doi:10.4103/1673-5374.230276 · Cited by 153
“APP is a type I, single-pass transmembrane protein with a large extracellular domain, a short cytoplasmic tail and is encoded by a single gene (Goldgaber et al., 1987; Kang et al., 1987; Tanzi et al., 1987).”
BackgroundGajdusek, D. C. (1988) · Journal of Neuroimmunology · doi:10.1016/0165-5728(88)90140-3 · Cited by 169
Protein precipitation: a common etiology in neurodegenerative disorders?
Kakizuka, A. (1998) · Trends in Genetics · doi:10.1016/s0168-9525(98)01559-5 · Cited by 163
Gorevic, P. D., Castaño, E. M., Sarma, R., & Frangione, B. (1987) · Biochemical and Biophysical Research Communications · doi:10.1016/0006-291x(87)91008-4 · Cited by 171
Puig, K. L., Floden, A. M., Adhikari, R., Golovko, M. Y., & Combs, C. K. (2012) · PLoS ONE · doi:10.1371/journal.pone.0030378 · Cited by 152
“where it can be metabolized to Aβ1-40 and 1-42 peptides which aggregate to form amyloid plaques characteristic of AD”
BackgroundVitamin A and Alzheimer's disease
Ono, K., & Yamada, M. (2012) · Geriatrics & Gerontology International · doi:10.1111/j.1447-0594.2011.00786.x · Cited by 151
Nagai, A., Nakagawa, E., Hatori, K., Choi, H. B., McLarnon, J. G., Lee, M. A., & Kim, S. U. (2001) · Neurobiology of Disease · doi:10.1006/nbdi.2001.0437 · Cited by 152
C-Terminal PEG Blocks the Irreversible Step in β-Amyloid(10-35) Fibrillogenesis
Burkoth, T. S., Benzinger, T. L. S., Jones, D. N. M., Hallenga, K., Meredith, S. C., & Lynn, D. G. (1998) · Journal of the American Chemical Society · doi:10.1021/ja980566b · Cited by 162
De Strooper, B., Umans, L., Van Leuven, F., & Van Den Berghe, H. (1993) · The Journal of cell biology · doi:10.1083/jcb.121.2.295 · Cited by 123
CSF biomarkers for mild cognitive impairment
Blennow, K. (2004) · Journal of Internal Medicine · doi:10.1111/j.1365-2796.2004.01368.x · Cited by 151
Portelius, E., Tran, A. J., Andreasson, U., Persson, R., Brinkmalm, G., Zetterberg, H., Blennow, K., & Westman-Brinkmalm, A. (2007) · Journal of Proteome Research · doi:10.1021/pr0703627 · Cited by 151
Mitomo, K., Kohzo, N., Kotaro, F., Xiangao, S., Shuji, S., & Yamamoto, K.-I. (1994) · Gene · doi:10.1016/0378-1119(94)90005-1 · Cited by 162
Complementary DNA for the mouse homolog of the human amyloid beta protein precursor
Yamada, T., Sasaki, H., Furuya, H., Miyata, T., Goto, I., & Sakaki, Y. (1987) · Biochemical and Biophysical Research Communications · doi:10.1016/0006-291x(87)90419-0 · Cited by 164
M. McLoughlin, D., & C.J. Miller, C. (1996) · FEBS Letters · doi:10.1016/s0014-5793(96)01128-3 · Cited by 151
Reaume, A. G., Howland, D. S., Trusko, S. P., Savage, M. J., Lang, D. M., Greenberg, B. D., Siman, R., & Scott, R. W. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.38.23380 · Cited by 150
Interactions between Alzheimer's disease and cerebral ischemia—focus on inflammation
Koistinaho, M., & Koıstınaho, J. (2005) · Brain Research Reviews · doi:10.1016/j.brainresrev.2004.12.014 · Cited by 162
Mori, T., Miyashita, N., Im, W., Feig, M., & Sugita, Y. (2016) · Biochimica et Biophysica Acta (BBA) - Biomembranes · doi:10.1016/j.bbamem.2015.12.032 · Cited by 160
“-secretase then cleaves the transmembrane -site (Gly38-Thr43), which prodices A peptides, primarily, A1-40 and A1-42 that aggregate in the later process [218-220].”
β‐Amyloid Precursor Protein Isoforms in Various Rat Brain Regions and During Brain Development
Löffler, J., & Huber, G. (1992) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.1992.tb08443.x · Cited by 150
“…protein, is a proteolytic fragment of a large 8- amyloid precursor protein (p-APP), the primary structure of which has the characteristics of an integral membrane protein, with the N-terminal part protruding into the extracellular space and a short C-terminal cytoplasmic tail (Kang et al., 1987).”
BackgroundExpression of APP in the early stage of brain damage
Kawarabayashi, T., Shoji, M., Harigaya, Y., Yamaguchi, H., & Hirai, S. (1991) · Brain Research · doi:10.1016/0006-8993(91)91558-i · Cited by 154
Abraham, C. R., Shirahama, T., & Potter, H. (1990) · Neurobiology of Aging · doi:10.1016/0197-4580(90)90045-2 · Cited by 150
Biomarkers used in Alzheimer’s disease diagnosis, treatment, and prevention
Mahaman, Y. A. R., Embaye, K. S., Huang, F., Li, L., Zhu, F., Wang, J.-Z., Liu, R., Feng, J., & Wang, X. (2022) · Ageing Research Reviews · doi:10.1016/j.arr.2021.101544 · Cited by 149
Neurodegeneration in Normal Brain Aging and Disease
Thal, D. R., Del Tredici, K., & Braak, H. (2004) · Science of Aging Knowledge Environment · doi:10.1126/sageke.2004.23.pe26 · Cited by 149
Kinetics of aggregation of synthetic β-amyloid peptide
Tomski, S. J., & Murphy, R. M. (1992) · Archives of Biochemistry and Biophysics · doi:10.1016/0003-9861(92)90735-f · Cited by 149
Chromosome Missegregation and Trisomy 21 Mosaicism in Alzheimer's Disease
Geller, L. N., & Potter, H. (1999) · Neurobiology of Disease · doi:10.1006/nbdi.1999.0236 · Cited by 149
“…the major component of the pathological amyloid deposits found in AD brain) resides on chromosome 21 and is overexpressed in Down syndrome individuals (Goldgaber et al., 1987; Kang et al., 1987; Robakis et al., 1987; Tanzi et al., 1987; Neve et al., 1988; Rumble et al., 1989; Oyama et al., 1994).”
BackgroundTomita, S., Ozaki, T., Taru, H., Oguchi, S., Takeda, S., Yagi, Y., Sakiyama, S., Kirino, Y., & Suzuki, T. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.4.2243 · Cited by 149
King, G. D., & Turner, R. S. (2004) · Experimental Neurology · doi:10.1016/j.expneurol.2003.10.011 · Cited by 170
Reversible Random Coil-.beta.-Sheet Transition of the Alzheimer .beta.-Amyloid Fragment (25-35)
Terzi, E., Hoelzemann, G., & Seelig, J. (1994) · Biochemistry · doi:10.1021/bi00172a009 · Cited by 167
Defining Molecular Targets to Prevent Alzheimer Disease
Selkoe, D. J. (2005) · Archives of Neurology · doi:10.1001/archneur.62.2.192 · Cited by 149
“In particular, the isolation and partial sequencing of the amyloid -protein (A ) by Glenner and Wong,(1) followed by the recognition that amyloid plaques (but not neurofibrillary tangles) were composed of the same protein, led to the cloning of the -amyloid precursor protein (APP) and the localization of its gene to h…”
BackgroundAβ aggregation and possible implications in Alzheimer's disease pathogenesis
Bharadwaj, P. R., Dubey, A. K., Masters, C. L., Martins, R. N., & Macreadie, I. G. (2009) · Journal of Cellular and Molecular Medicine · doi:10.1111/j.1582-4934.2009.00609.x · Cited by 146
Self-citationAskanas, V., Engel, W. K., & Alvarez, R. B. (1992) · PubMed · Cited by 159
Binding of cystatin C to Alzheimer’s amyloid β inhibits in vitro amyloid fibril formation
Sastre, M., Calero, M., Pawlik, M., Mathews, P. M., Kumar, A. R., Danilov, V., Schmidt, S. D., Nixon, R. A., Frangione, B., & Levy, E. (2004) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2003.11.006 · Cited by 151
“It is a processing product of a larger amyloid precursor protein ( APP) [29].”
BackgroundDe Jonghe, C., Zehr, C., Yager, D., Prada, C.-M., Younkin, S., Hendriks, L., Van Broeckhoven, C., & Eckman, C. B. (1998) · Neurobiology of Disease · doi:10.1006/nbdi.1998.0202 · Cited by 148
“APP is a glycosylated type I membrane protein with a single transmembrane domain appearing in different isoforms of which the one with 695 amino acids (APP695) is most abundant in brain (Kang et al., 1987).”
BackgroundMann, D. M. A., Jones, D., Prinja, D., & Purkiss, M. (1990) · Acta Neuropathologica · doi:10.1007/bf00294651 · Cited by 152
“It is tacitly accepted by many that it is of neuronal origin and may be deposited as a result of damage to nerve cell surface membranes [ 19 ].”
BackgroundHampel, H., O’Bryant, S. E., Durrleman, S., Younesi, E., Rojkova, K., Escott-Price, V., Corvol, J.-C., Broich, K., Dubois, B., Lista, S., et al. (2017) · Climacteric · doi:10.1080/13697137.2017.1287866 · Cited by 147
“According to the Food and Drug Administration (FDA) and the NIH Biomarkers, Endpoints, and other Tools (BEST) Resource, biomarker categories can be divided into the following categories: (1) susceptibility/risk biomarker, (2) diagnostic biomarker, (3) monitoring biomarker, (4) prognostic biomarker, (5) predictive biom…”
BackgroundCoexistence of Alzheimer-type neuropathology in Creutzfeldt-Jakob disease
Hainfellner, J. A., Wanschitz, J., Jellinger, K. A., Liberski, P. P., Gullotta, F., & Budka, H. (1998) · Acta Neuropathologica · doi:10.1007/s004010050870 · Cited by 160
“In AD, the major component of plaques is amyloid β/A4 peptide, which is proteolytically cleaved from a cell membrane spanning precursor glycoprotein [ 15 ].”
A voxel-based morphometric study of nondemented adults with Down Syndrome
White, N. S., Alkire, M. T., & Haier, R. J. (2003) · NeuroImage · doi:10.1016/s1053-8119(03)00273-8 · Cited by 169
“All DS individuals by the 4th decade show some degree of tangle and plaque neuropathology similar to that of AD (Wisniewski et al., 1985) which is due to the overexpression of the amyloid precursor protein gene location on chromo- some 21 (Kang et al., 1987; Tanzi et al., 1988).”
BackgroundThe X-Ray Structure of an Antiparallel Dimer of the Human Amyloid Precursor Protein E2 Domain
Wang, Y., & Ha, Y. (2004) · Molecular Cell · doi:10.1016/j.molcel.2004.06.037 · Cited by 181
Potter, H. (1991) · Europe PMC (PubMed Central) · Cited by 149
Ohsawa, I., Takamura, C., Morimoto, T., Ishiguro, M., & Kohsaka, S. (1999) · European Journal of Neuroscience · doi:10.1046/j.1460-9568.1999.00601.x · Cited by 147
“b-Amyloid is derived from amyloid precursor protein (APP), which is expressed as integral membrane glycoproteins (Goldgaber et al., 1987; Kang et al., 1987; Tanzi et al., 1987).”
BackgroundD'Andrea, M., & Nagele, R. (2006) · Current Pharmaceutical Design · doi:10.2174/138161206775474224 · Cited by 146
Presenilin-1 differentially facilitates endoproteolysis of the β-amyloid precursor protein and Notch
Capell, A., Steiner, H., Romig, H., Keck, S., Baader, M., Grim, M. G., Baumeister, R., & Haass, C. (2000) · Nature Cell Biology · doi:10.1038/35008626 · Cited by 166
“Whereas cleavage of b-APP occurs within the membrane, cleavage of Notch is located close to or at the membran”
Hornsten, A., Lieberthal, J., Fadia, S., Malins, R., Ha, L., Xu, X., Daigle, I., Markowitz, M., O'Connor, G., Plasterk, R., et al. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0603997104 · Cited by 145
THE GENETICS AND MOLECULAR PATHOLOGY OF ALZHEIMER'S DISEASE
Selkoe, D. J. (2000) · Neurologic Clinics · doi:10.1016/s0733-8619(05)70232-2 · Cited by 162
Luo, L., Martin-Morris, L., & White, K. (1990) · The Journal of Neuroscience · doi:10.1523/jneurosci.10-12-03849.1990 · Cited by 146
Amyloid precursor protein in aged nonhuman primates.
Martin, L. J., Sisodia, S. S., Koo, E. H., Cork, L. C., Dellovade, T. L., Weidemann, A., Beyreuther, K., Masters, C., & Price, D. L. (1991) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.88.4.1461 · Cited by 146
Self-citationHaass, C., & Selkoe, D. (2022) · PLOS Biology · doi:10.1371/journal.pbio.3001694 · Cited by 145
“When scientists cloned APP, they quickly learned that the gene is located on chromosome 21 [11], a finding that was important because patients with trisomy 21 have Down syndrome and invariably develop neuropathological and clinical signs of early-onset AD, starting in their 40s or earlier.”
BackgroundEvidence for intracellular cleavage of the Alzheimer's amyloid precursor in PC12 cells
Sambamurti, K., Shioi, J., Anderson, J. P., Pappolla, M. A., & Robakis, N. K. (1992) · Journal of Neuroscience Research · doi:10.1002/jnr.490330216 · Cited by 145
Proteinopathies, a core concept for understanding and ultimately treating degenerative disorders?
Bayer, T. A. (2015) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2013.03.007 · Cited by 140
“Notch 3 Notch 3 isolation and sequencing of the gene encoding the larger amyloid precursor protein (APP) (Kang et al., 1987; Tanzi et al., 1987).”
BackgroundPhysiology and pharmacology of amyloid precursor protein
Cho, Y., Bae, H.-G., Okun, E., Arumugam, T. V., & Jo, D.-G. (2022) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2022.108122 · Cited by 142
Alzheimer's Disease and the Amyloid β Protein: What Is the Role of Amyloid ?
Small, D. H., & McLean, C. A. (1999) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.1999.0730443.x · Cited by 143
Bieschke, J., Zhang, Q., Powers, E. T., Lerner, R. A., & Kelly, J. W. (2005) · Biochemistry · doi:10.1021/bi0501030 · Cited by 144
Nostrand, W. E. V., Wagner, S. L., Farrow, J. S., & Cunningham, D. D. (1990) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(19)38706-x · Cited by 154
Roberts, B. R., Lind, M., Wagen, A. Z., Rembach, A., Frugier, T., Li, Q.-X., Ryan, T. M., McLean, C. A., Doecke, J. D., Rowe, C. C., et al. (2017) · Brain · doi:10.1093/brain/awx057 · Cited by 143
Self-citationPierrot, N., Ghisdal, P., Caumont, A., & Octave, J. (2004) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2003.02227.x · Cited by 143
“In neurones, APP is a 695-amino acid type I transmembrane protein (APP695) (Kang et al. 1987) with a large N-terminal ectodomain and a short intracellular C-terminus.”
BackgroundKienlen-Campard, P., Tasiaux, B., Van Hees, J., Li, M., Huysseune, S., Sato, T., Fei, J. Z., Aimoto, S., Courtoy, P. J., Smith, S. O., et al. (2008) · Journal of Biological Chemistry · doi:10.1074/jbc.m707142200 · Cited by 142
Masters, C. L., & Beyreuther, K. (2006) · Brain · doi:10.1093/brain/awl251 · Cited by 141
“After the initial sequencing of the N-terminus of Ab derived from cerebral leptomeninges (Glenner and Wong, 1984a, b), we were able to correct and extend the sequence of plaque-derived amyloid, and determine the likely C-terminus (Masters et al., 1985a,b; Kang et al., 1987).”
InfluentialSelf-citationYAMAGUCHI, H., Nakazato, Y., Hirai, S., Shoji, M., & Harigaya, Y. (1989) · Europe PMC (PubMed Central) · Cited by 143
Tamaoka, A., Kalaria, R. N., Lieberburg, I., & Selkoe, D. J. (1992) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.89.4.1345 · Cited by 143
Johnston, J. A., Cowburn, R. F., Norgren, S., Wiehager, B., Venizelos, N., Winblad, B., Vigo-Pelfrey, C., Schenk, D., Lannfelt, L., & O'Neill, C. (1994) · FEBS Letters · doi:10.1016/0014-5793(94)01137-0 · Cited by 115
Amyloid protein and neurofibrillary tangles coexist in the same neuron in Alzheimer disease.
Grundke-Iqbal, I., Iqbal, K., George, L., Tung, Y. C., Kim, K. S., & Wisniewski, H. M. (1989) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.86.8.2853 · Cited by 141
Wu, D., Yang, J., & Pardridge, W. M. (1997) · Journal of Clinical Investigation · doi:10.1172/jci119708 · Cited by 142
Selective ectodomain phosphorylation and regulated cleavage of beta‐amyloid precursor protein.
Hung, A. Y., & Selkoe, D. J. (1994) · The EMBO Journal · doi:10.1002/j.1460-2075.1994.tb06291.x · Cited by 178
Deposits of Amyloid β Protein in the Central Nervous System of Transgenic Mice
Wirak, D. O., Bayney, R., Ramabhadran, T. V., Fracasso, R. P., Hart, J. T., Hauer, P. E., Hsiau, P., Pekar, S. K., Scangos, G. A., Trapp, B. D., et al. (1991) · Science · doi:10.1126/science.1857970 · Cited by 142
Self-citationRusek, M., Smith, J., El-Khatib, K., Aikins, K., Czuczwar, S. J., & Pluta, R. M. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24010864 · Cited by 154
Di Luca, M. (1998) · Archives of Neurology · doi:10.1001/archneur.55.9.1195 · Cited by 142
Matsuda, S., Giliberto, L., Matsuda, Y., Davies, P., McGowan, E., Pickford, F., Ghiso, J., Frangione, B., & D'Adamio, L. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.c500217200 · Cited by 141
Statins as potential therapeutic agents in neuroinflammatory disorders
Stüve, O., Youssef, S., Steinman, L., & Zamvil, S. S. (2003) · Current Opinion in Neurology · doi:10.1097/01.wco.0000073942.19076.d1 · Cited by 141
Preliminary studies of a novel bifunctional metal chelator targeting Alzheimer's amyloidogenesis
Dedeoglu, A., Cormier, K., Payton, S., Tseitlin, K. A., Kremsky, J. N., Lai, L., Li, X., Moir, R. D., Tanzi, R. E., Bush, A. I., et al. (2004) · Experimental Gerontology · doi:10.1016/j.exger.2004.08.016 · Cited by 141
“APP gene is the first AD-associated gene that has been identified and its mutations cause early onset AD (Kang et al., 1987; Robakis et al., 1987; Tanzi et al., 1987, 1988).”
(1990) · PubMed Central
Deciphering Alzheimer's Disease: The Amyloid Precursor Protein Yields New Clues
Selkoe, D. J. (1990) · Science · doi:10.1126/science.2111582 · Cited by 141
Shringarpure, R., Grune, T., Sitte, N., & Davies*, K. J. A. (2000) · Cellular and Molecular Life Sciences · doi:10.1007/pl00000660 · Cited by 140
Abolhassani, N., Leon, J., Sheng, Z., Oka, S., Hamasaki, H., Iwaki, T., & Nakabeppu, Y. (2017) · Mechanisms of Ageing and Development · doi:10.1016/j.mad.2016.05.005 · Cited by 140
“Individuals with mutations in any of these three dominantly inherited genes, tend to develop AD symptoms before the age of 65, sometimes as early as age 30, and it has been shown that A plaques can be present for more than 20 years before the onset of dementia in patients with such inherited mutations (Bateman et al.,…”
BackgroundGralle, M., Botelho, M. G., & Wouters, F. S. (2009) · Journal of Biological Chemistry · doi:10.1074/jbc.m808755200 · Cited by 125
Impact of social relationships on Alzheimer’s memory impairment: mechanistic studies
Hsiao, Y.-H., Chang, C.-H., & Gean, P.-W. (2018) · Journal of Biomedical Science · doi:10.1186/s12929-018-0404-x · Cited by 139
Lee, M.-C., Yu, W.-C., Shih, Y.-H., Chen, C.-Y., Guo, Z.-H., Huang, S.-J., Chan, J. C. C., & Chen, Y.-R. (2018) · Scientific Reports · doi:10.1038/s41598-018-23122-x · Cited by 134
Intraneuronal compartments of the amyloid precursor protein
Ferreira, A., Caceres, A., & Kosik, K. (1993) · The Journal of Neuroscience · doi:10.1523/jneurosci.13-07-03112.1993 · Cited by 114
Zloković, B. V. (1996) · Life Sciences · doi:10.1016/0024-3205(96)00310-4 · Cited by 152
Progressive brain dysfunction following intracerebroventricular infusion of beta1–42-amyloid peptide
Nakamura, S., Murayama, N., Noshita, T., Annoura, H., & Ohno, T. (2001) · Brain Research · doi:10.1016/s0006-8993(01)02704-4 · Cited by 166
YAMAGUCHI, H., Hirai, S., Morimatsu, M., Shoji, M., & Nakazato, Y. (1989) · Acta Neuropathologica · doi:10.1007/bf00687584 · Cited by 139
“A rabbit was immunized with a synthetic peptide consisting of residues 1-28 of fl protein [4] to which keyhole limpet hemocyanin was coupled through the N-terminal cysteine [20].”
BackgroundMethodNinomiya, H., Roch, J. M., Sundsmo, M. P., Otero, D. A., & Saitoh, T. (1993) · The Journal of cell biology · doi:10.1083/jcb.121.4.879 · Cited by 139
Zhao, L., Wang, J., Wang, Y.-R., & Fa, X.-Z. (2012) · Brain Research · doi:10.1016/j.brainres.2012.11.019 · Cited by 146
Astrocytes in Alzheimer's disease gray matter express alpha 1-antichymotrypsin mRNA.
Pasternack, J. M., Abraham, C. R., Dyke, B. J. V., Potter, H., & Younkin, S. G. (1989) · PubMed · Cited by 140
The Amyloid β Protein Gene Is Not Duplicated in Brains from Patients with Alzheimer's Disease
Tanzi, R. E., Bird, E. D., Latt, S. A., & Neve, R. L. (1987) · Science · doi:10.1126/science.2890207 · Cited by 140
Metadata
- Authors
- Kang, J., Lemaire, H.-G., Unterbeck, A., Salbaum, J. M., Masters, C. L., Grzeschik, K.-H., Multhaup, G., Beyreuther, K., & Müller-Hill, B.
- Affiliations
- University of Cologne (DE)
- Venue
- Nature
- Published
- 1987-02
- Volume
- 325
- Issue
- 6106
- Pages
- 733-736
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- OpenAlex
- W2081881251
- Cited by
- 4,619
- References
- 26
- Citations by year
- 2026: 38 · 2025: 58 · 2024: 63 · 2023: 71 · 2022: 54 · 2021: 79 · 2020: 82 · 2019: 76 · 2018: 76 · 2017: 98 · 2016: 111 · 2015: 90 · 2014: 97 · 2013: 119 · 2012: 126
- FWCI
- 164.88
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
- Keywords
- Alzheimer's disease, amyloid precursor protein, cell surface receptors, Down syndrome, amyloid plaques, neurofibrillary tangles, chromosome 21, cDNA cloning, protein sequences
- MeSH terms
- Alzheimer Disease, Amyloid, Base Sequence, Brain, Brain Chemistry, Chromosomes, Human, Pair 21, DNA, Down Syndrome, Fetus, Humans, Neurofibrils, Nucleic Acid Hybridization, Protein Precursors, Protein Processing, Post-Translational, RNA, Messenger, Amyloid beta-Peptides, Amyloid beta-Protein Precursor
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.